Home

Baker Bros. Capital (GP), LLC

CIK 1244390 · last filed 2012-01-04

Baker Bros. Capital (GP), LLC is a corporate insider who has filed 18 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing shows the insider exercised options on $1.3M of SGEN on Jan 4, 2012. Across all open-market trades the lifetime net is −$726.6K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $36.1M across reported positions. The firm reports its address in New York, NY. 170 SEC filings were submitted jointly with JULIAN BAKER.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$36.14M

Companies

8

Total Filings

18

Lifetime Open-Market Net

-$726.6K

Filer Profile

Reported Address
667 MADISON AVE
21ST FLOOR
NEW YORK, NY 10065
Phone
(212) 339-5600
State of Incorporation
DE
Formerly Known As
BAKER BROS CAPITAL GP LLC (2003–2005)
Related Filers
JULIAN BAKER — 170 joint filings, latest 2012-01-31
FELIX BAKER — 155 joint filings, latest 2012-01-31
INCYTE CORP — 26 joint filings, latest 2011-07-05
14159 capital (GP), LLC — same reported address
Baker / Tisch Capital (GP), LLC — same reported address
Baker Biotech Capital (GP), LLC — same reported address
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Seagen Inc. (SGEN) Delisted Director 539,130 $228.74 $123.32M $119.4K 3 2012-01-04
BCRX 10%+ Owner 62,407 $9.03 $563.5K $0 1 2011-07-05
GENOMIC HEALTH INC (GHDX) Delisted Director 194,415 — — $9.4K 2 2011-06-09
VIROPHARMA INC (VPHM) Delisted 10%+ Owner 105,694 — — -$428.5K 2 2009-05-20
INCY Director 284,025 $125.26 $35.58M $46.2K 4 2008-12-22
Aceragen, Inc. (IDRA) Delisted 10%+ Owner 3,098 $7.22 $22.4K -$75.2K 1 2008-07-16
Ardea Biosciences, Inc./DE (RDEA) Delisted 10%+ Owner 163,256 — — $81.8K 2 2008-05-30
Aceragen, Inc. (IDP) Delisted 10%+ Owner 95,563 — — -$479.6K 2 2007-12-07

Recent Filings

18 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2012-01-04 Seagen Inc. (SGEN) Delisted Exer (X) +204,018 $1.28M EDGAR
2011-07-05 BCRX Other (J) −28,770 $0 EDGAR
2011-06-09 GENOMIC HEALTH INC (GHDX) Delisted Buy (P) +357 $9.4K EDGAR
2009-05-20 VIROPHARMA INC (VPHM) Delisted Buy (P) +324 $1.9K EDGAR
2009-05-20 Seagen Inc. (SGEN) Delisted Buy (P) +11,130 $108.2K EDGAR
2008-12-22 INCY Buy (P) +2,517 $8.8K EDGAR
2008-07-16 Aceragen, Inc. (IDRA) Delisted Sell (S) −4,935 -$75.2K EDGAR
2008-05-30 — Other (J) −106,641 $0
2008-05-30 Ardea Biosciences, Inc./DE (RDEA) Delisted Other (J) −94,518 $0 EDGAR
2008-03-14 Seagen Inc. (SGEN) Delisted Buy (P) +1,392 $11.2K EDGAR
Showing 1–10 of 18
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.